Multi-Institution Analysis of Tarlatamab for the Treatment of -Mutant Transformed Small Cell Lung Cancer.

JCO precision oncology 2025 Oct 30

Multi-Institution Analysis of Tarlatamab for the Treatment of -Mutant Transformed Small Cell Lung Cancer.

Related Questions

In cases where EGFR NSCLC has transformed into small-cell lung cancer after treatment with osimertinib, and with no CNS involvement, is it advisable to continue osimertinib alongside chemotherapy?

Furthermore, should adding immunotherapy be considered?

New answer by Medical Oncologist at Cancer Care Specialists/Renown Oncology/UNR (November 2, 2025)

Also, tarlatamab doesn’t work well in these despite high DLL3 expression, per this small series Cooper et al., PMID 41166675.

Read more (2 Answers available)

Would you offer tarlatamab to patients with metastatic EGFR+ NSCLC that transformed into SCLC?

New answer by Medical Oncologist at The University of Texas MD Anderson Cancer Center (November 18, 2025)

Yes, in fact, we recently collaborated on a multi-institutional report of a small cohort of such patients and have tried it a few additional times since then for patients with...

Read more (1 Answer available)